2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

2:30PM-4:00PM: Abstract Number: 2759

The Risk of Ischaemic Stroke in Primary APS Patients: A Prospective Study

Antiphospholipid Syndrome

2:30PM-4:00PM: Abstract Number: 2788

The Risk of Major Toxicity with Aspirin for Primary Cardiovascular Prevention in Rheumatoid Arthritis Patients Using Nsaids: A Secondary Cohort Analysis of a Randomized Controlled Clinical Trial

Rheumatoid Arthritis – Clinical Aspects IV: Medications and Risk

2:30PM-4:00PM: Abstract Number: 2786

Timing of Abatacept Infusions before Elective Arthroplasty and the Risk of Post-Operative Infection

Rheumatoid Arthritis – Clinical Aspects IV: Medications and Risk

2:30PM-4:00PM: Abstract Number: 2787

Tuberculosis, Potential Opportunistic Infections, and Other Infections of Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program

Rheumatoid Arthritis – Clinical Aspects IV: Medications and Risk

2:30PM-4:00PM: Abstract Number: 2772

Unbound IL-18 Distinguishes Human Macrophage Activation Syndrome from Familial Hemophagocytic Lymphohistiocytosis and Affects Innate Versus Adaptive Murine Lymphocytes Differently

Innate Immunity and Rheumatic Disease

2:30PM-4:00PM: Abstract Number: 2770

Using Fitbits. Fitabase®, and Remote Coaching to Increase Physical Activity in Employees with Knee Osteoarthritis Symptoms

ARHP Rehabilitation Science

4:30PM-6:00PM: Abstract Number: 2835

5-Year Evolution Patterns of Physical Activity and Sedentary Behavior of Patients with Symptomatic Hip and/or Knee Osteoarthritis, and Their Sociodemographic and Clinical Correlates

Health Services Research I: Cost Drivers in Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 2828

A Graph-Theoretic-Approach Applied to Modular-Repertoire-Analysis Identifies Shared Gradual Whole Blood Interferon Signatures in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome Patients and Reveals New Interferon-Related Modules in Disease Progression

Genetics, Genomics and Proteomics

4:30PM-6:00PM: Abstract Number: 2821

A Multidisciplinary Telemedicine Program for Identification of Spondyloarthritis in Medically Underserviced Communities

ARHP: Exemplary Abstracts

4:30PM-6:00PM: Abstract Number: 2827

A Novel Statistical Method to Resolve Cellular Heterogeneity in Disease Tissues: Integrating Transcriptomic Data in Accelerating Medicines Partnership (AMP) – RA Network Phase 1 Data

Genetics, Genomics and Proteomics

4:30PM-6:00PM: Abstract Number: 2884

A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics II

4:30PM-6:00PM: Abstract Number: 2825

A Possible Environmental Origin for a Proportion of the Genetic Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus

Genetics, Genomics and Proteomics

4:30PM-6:00PM: Abstract Number: 2822

A Randomized Controlled Effectiveness Trial of the Enhance-Fitness® Physical Activity Program in People with Arthritis

ARHP: Exemplary Abstracts

4:30PM-6:00PM: Abstract Number: 2889

Aminaphtone Ameliorates Clinical Symptoms and Increases Skin Blood Perfusion in Patients with Both Primary and Secondary Raynaud Phenomenon: A Six-Month Open Study

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics II

4:30PM-6:00PM: Abstract Number: 2876

Analysis of Autoantibody Reactivity to the Complete Human Peptidome By Phage Immunoprecipitation Sequencing Does Not Identify a Predominant Novel Autoantibody in Sjogren’s Syndrome

Sjögren's Syndrome II: Pathogenesis, Autoantibodies and T-Cells

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].